Influx Healthtech Ltd.

Regd. Office : 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.
Factory : Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.
Contact No. : +91 9820201063 / 8080333319 / 8411879521
Email : influxhealthtech@gmail.com/ influxhealthcare1@gmail.com
Website : www.influxhealthtech.com
CIN : U24299MH2020PLC346825

October 16, 2025

To,
Listing Department,
National Stock Exchange Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai-400 051

Scrip Code – INFLUX

Dear Sir/Madam,

Sub.: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform our stakeholders that **Influx Healthtech Limited ("the Company")** has received the **Food and Safety Standards Authority of India (FSSAI) license** on October 14, 2025 for its newly established rented facility, authorizing the Company to commence tablet manufacturing operations at the new facility Situated at Shed No A/13, Gat No 248/250/56, Kolgaon, Palghar, Maharashtra 400067.

The new facility is equipped with advanced manufacturing and quality control systems, marks a significant milestone in the Company's capacity expansion and modernization initiative aimed at strengthening its manufacturing capabilities in the **nutraceutical segment.**

With the addition of the new tablet manufacturing line, the Company's overall production capacity is expected to increase by approximately 10,000–15,000 bottles per day, with the option to scale up further in the future.

This expansion is expected to:

a. Enhance overall production capacity and efficiency.
b. Reduce manufacturing lead time, strengthen supply reliability, and improve economies of scale.
c. Support higher output and revenue growth in the coming financial periods.

Influx Healthtech Ltd.

Regd. Office : 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.
Factory : Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.
Contact No. : +91 9820201063 / 8080333319 / 8411879521
Email : influxhealthtech@gmail.com/ influxhealthcare1@gmail.com
Website : www.influxhealthtech.com
CIN : U24299MH2020PLC346825

The Company remains committed to adhering to all statutory and regulatory requirements, maintaining the highest standards of quality and compliance.

This development marks a key step in the Company's strategic roadmap to strengthen its position as a leading Contract Development and Manufacturing Organization (CDMO) in nutraceuticals, cosmetics, and veterinary formulation.

The details as per requirement of Regulation 30 of Listing Regulations read with SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is given in "Annexure A" and "Annexure B".

We request you to take the above information on record.

Thanking you,

For Influx Healthtech Limited,

Munir Abdul Ganee Chandniwala

Digitally signed by Munir Abdul Ganee Chandniwala
Date: 2025.10.16 13:15:32 +05'30'

Munir Abdul Ganee Chandniwala
Managing Director
DIN: 08459582

For further information, please contact

Influx Healthtech Ltd.

Company
Influx Healthtech Limited
Ashish Shah
Chief Financial Officer
cs@influxhealthtech.com

CAPITAL BRIDGE ADVISORS

Investor relations consultants
Capital Bridge Advisory Service Private Limited
Mr. Rutul Shah
(E) rutul@capbridge.in
(M) +91 820 024 7366

Mr. Raj Shah, CFA
(E) raj@capbridge.in
(M) +91 992 591 1296

Influx Healthtech Ltd.

Regd. Office : 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.
Factory : Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.
Contact No. : +91 9820201063 / 8080333319 / 8411879521
Email : influxhealthtech@gmail.com/ influxhealthcare1@gmail.com
Website : www.influxhealthtech.com
CIN : U24299MH2020PLC346825

Annexure-A

Additional Details as required under Regulation 30 and other relevant provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sr. No.	**Details of events that needs to be provided**	**Information of such event(s)**
1	Name of the regulatory or licensing authority	Food Safety and Standards Authority of India
2	Brief details of the ~~approval~~/license obtained~~/ withdrawn/ surrendered~~	The Company has been granted license from Food Safety and Standards Authority of India for scope of **Manufacture of health, dietary and nutritional supplements (vitamins, minerals, amino acids and protein – tablet/capsule) for use in the food industry**
3	Impact/relevance of such ~~approval~~/license to the listed entity	This Certificate will enable Influx Healthtech Ltd. to legally operate its business in compliance with the FSS Act, 2006
4	Withdrawal/cancellation or suspension of license/approval by the regulatory or licensing authority, with reasons for such action, estimated impact (monetary or otherwise) on the listed entity and penalty, if any	Not Applicable
5	Period for which such ~~approval~~/license is/~~was~~ valid	5 Years (From: October 14, 2025 to: October 13, 2030)
6	Subsequently, the listed entity shall inform the stock exchange(s), the actual impact (monetary or otherwise) along with corrective actions taken by the listed entity pursuant to the withdrawal, cancellation or suspension of the key license/ approval	Not Applicable

Influx Healthtech Ltd.

Regd. Office : 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.
Factory : Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.
Contact No. : +91 9820201063 / 8080333319 / 8411879521
Email : influxhealthtech@gmail.com/ influxhealthcare1@gmail.com
Website : www.influxhealthtech.com
CIN : U24299MH2020PLC346825

Annexure-B

Additional Details as required under Regulation 30 and other relevant provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sr. No.	**Particulars**	**Details**
1.	Existing Capacity	The Existing Tablet Manufacturing Capacity is 20,000 bottles per day
2.	Existing Capacity Utilization	90%
3.	Proposed Capacity Addition	There is an addition of Approximately 10,000 – 15,000 bottles per day of tablet Manufacturing Capacity
4.	Period within which the proposed capacity is to be added	The new capacity has now been commissioned and is fully operational.
5.	Investment Required	The expansion entails total investment of Rs. 60 Lakhs
6.	Mode of Financing	The Project is fully funded through internal accruals
7.	Rationale	To meet surging demand, shorten lead times and reduce unit costs through economies of scale, Influx is expanding tablet Manufacturing capacity to Approximately 30,000 – 35,000 bottles per day at its new FSSAI-licensed facility.